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The guidelines have been extensively revised since the last edition in 2005; most 
sections have been amended and areas where there is a need for clinical trials or 
data have been highlighted. 
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The major changes/amendments are: 
 
 a more detailed discussion of gamma interferon tests; 
 new guidance on chemopreventative therapy 
 a complete update of the drug interactions section and tables;  
 an updated section on choice of NNRTI;  
 a revised section on when to start HAART; 
 a new section on isoniazid resistance and XDR; 
 guidance on the diagnosis of IRIS; 
 new tables for management of adverse reactions. 
  
1.0 Summary of guidelines 
 
These guidelines have been drawn up to help physicians manage adults with TB/HIV 
coinfection. Recommendations for the treatment of TB in HIV-infected adults are similar 
to those in HIV-negative adults. However, there are important exceptions which are 
discussed in this summary. We recommend that coinfected patients are managed by a 
multidisciplinary team which includes physicians with expertise in the treatment of both 
tuberculosis and HIV.  
We recommend using the optimal anti-tuberculosis regimen. In the majority of cases this 
will include rifampicin and isoniazid.  
In the treatment of HIV, patients starting highly active antiretroviral therapy (HAART) 
have an ever-greater choice of drugs. We recommend that if patients on anti-
tuberculosis therapy are starting HAART then antiretrovirals should be chosen to 
minimize interactions with TB therapy. There will be cases in which the choice of 
antiretrovirals is limited by intolerance, severe toxicity or genotypic resistance. TB 
treatment should only be modified when drug interactions with these antiretrovirals do 
not allow the optimal TB regimen. In some of these cases a longer duration of TB 
treatment may be necessary. 
 
1.1 Diagnosis of active TB 
The gold standard for diagnosing tuberculosis is microscopy followed by culture and 
drug sensitivity testing. Molecular diagnostics may be valuable when acid-fast bacilli are 
seen on smears. Rapid confirmation, by molecular diagnostics, that acid-fast bacilli are 
not M. tuberculosis, may avoid unnecessary treatment and infection-control measures.  
We recommend rapid detection of rifampicin resistance using molecular techniques in 
patients whose initial assessment (e.g., recent immigrant from an area with a high 
prevalence of rifampicin-resistant disease) or clinical course suggest multi-drug resistant 
tuberculosis. These molecular tests should be used as an adjunct to standard laboratory 
techniques.  
 
1.2 Detection of latent TB infection: Tuberculin skin test/interferon-γ assays 
HIV-infected individuals with latent TB infection are much more likely to progress to 
active TB than HIV-uninfected people. Detection and treatment of latent TB infection is 
therefore important, although diagnosis can be difficult.  
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Tuberculin skin test (TST)/interferon-γ assays (IGRAs) are used to detect latent 
infection. They are not recommended as a diagnostic tool in suspected active TB as they 
only reflect previous mycobacterial exposure. Tuberculin skin testing is less useful in 
patients with HIV infection compared with HIV-uninfected patients, especially at low CD4 
cell counts. IGRAs are newer blood assays from essentially MTB-specific T cells, which 
are generally more sensitive than tuberculin tests for detecting both active and latent 
disease in HIV-negative subjects. They are also more specific in BCG-vaccinated 
individuals. Although there are few data regarding their performance in HIV-infected 
patients, especially at low blood CD4 cell counts, we believe that IGRAs may have value 
in detecting latent TB infection and we recommend the use of IGRAs rather than TSTs 
as a screening tool for latent tuberculosis. However, their precise role remains unclear 
and draft NICE guidance suggests using IGRA testing in those patients with a CD4 
count over 200 cells/μL, and both an IGRA and tuberculin test in those with CD4 counts 
below this threshold. Although physicians can perform both tests in severely 
immunosuppressed patients, we believe that there are few data to support this strategy 
and doing this would add complexity, cost and difficulties in interpretation. The majority 
of the Committee believe that an IGRA test alone would be sufficient. New data would 
be welcome in guiding physicians in this difficult area. 
 
We recommend screening for latent infection in HIV-infected patients dependent on a 
risk assessment based on country of origin, blood CD4 cell count and length of time on 
antiretroviral therapy. In addition, all HIV-positive close contacts of people who have 
infectious TB should be followed up and offered chemo-preventative therapy according 
to NICE guidelines [1]. 
 
 
1.3 Treatment of latent TB infection 
Active TB needs to be excluded before considering treatment of latent infection, which is 
usually with isoniazid monotherapy for 6 months or isoniazid/rifampicin for 3 months. 
 
Starting HAART reduces the risk of reactivation of latent TB infection and is effective at 
reducing the incidence of new TB. We recommend that all HIV-positive patients should 
be offered HAART in line with the BHIVA guidelines.  
 
 
1.4 Treatment of active TB  
We recommend daily tuberculosis treatment whenever possible. Treatment may be 
given 5 days per week, but should be intensively supervised. This option may be useful 
in hospital or other highly supervised settings. Three-times-per-week directly observed 
therapy (DOT) should only be given to patients who are stable and clinically well and 
where local logistics enable this to be undertaken successfully 
We do not recommend twice-weekly DOT for treatment of HIV/TB coinfected patients, 
especially in those with CD4 counts <100 cells/μL, since it has been associated with 
unacceptably high rates of rifamycin resistance.  
 
In cases where multiple drug resistance is not suspected, treatment should be started 
with four drugs (typically rifampicin, isoniazid, pyrazinamide and ethambutol) until 
sensitivities are known.  
We recommend a 6-month treatment regimen for drug-sensitive TB outside of the 
central nervous system (CNS). This is usually four drugs for 2 months, followed by 
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isoniazid and rifampicin for a further 4 months (at least 182 doses of isoniazid and 
rifampicin and 56 doses of pyrazinamide and ethambutol in total).  
In drug-sensitive TB affecting the CNS we recommend 9 months of treatment. This 
usually consists of four drugs for 2 months, followed by 7 months of isoniazid and 
rifampicin [2].  
Drug resistant disease should be treated by only specialists with experience in such 
cases, in line with NICE guidelines [1]. 
 
1.5 Drug interactions and toxicities 
Careful attention should be paid to drug interactions between TB drugs, HAART and 
other therapy. Rifampicin is a powerful inducer of CYP450 and has effects on several 
metabolic pathways and PgP. Rifampicin interacts with protease inhibitors, NNRTIs, 
CCR5 antagonists, and antimicrobials such as fluconazole. Rifabutin is a less potent 
inducer of CYP450 and may be used as an alternative to overcome some of these 
difficulties. (For up-to-date drug interaction data go to www.hiv-druginteractions.org) 
Toxicity profiles of antiretrovirals and anti-TB drugs overlap and make it difficult to 
determine the causative drug. For example, rashes occur with NNRTIs, rifampicin and 
isoniazid. Isoniazid and stavudine both cause peripheral neuropathy. All patients on 
isoniazid should take pyridoxine to try and prevent this complication. Patients with 
chronic liver disease have higher rates of toxicity and need more frequent monitoring of 
liver function tests. Drug absorption may be affected by advanced HIV disease. 
 
1.6 Antiretroviral treatment 
Rifamycin-based TB regimens should be used whenever possible. Coadministration 
guidance for first-line antiretrovirals is given below. There are few long-term clinical 
outcome data to support use of these TB/HIV drug combinations.  
 
1.6.1 Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) 
There are no major interactions between rifampicin or rifabutin and lamivudine (3TC), 
emtricitabine (FTC), tenofovir, abacavir, zidovudine (AZT) or didanosine (ddI).  
Stavudine (d4T) should not be given because of the increased risk of peripheral 
neuropathy with concomitant TB therapy. 
 
1.6.2 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
The preferred regimen for patients who have no contraindication is:  
Rifampicin + Efavirenz Use efavirenz 800mg/day in patients weighing >60kg and 
standard dose 600mg/day in patients weighing <60kg  
If side effects occur, efavirenz TDM may be useful 
Other regimens include:  
Rifampicin + Nevirapine*  Not recommended but if given then use standard doses 
and perform nevirapine TDM 
Rifabutin + Efavirenz  Increase rifabutin to 450mg daily 
Rifabutin + Nevirapine*  Not recommended but if given then use standard doses  
  
1.6.3 Protease inhibitors (PI) 
Rifampicin + unboosted PI  Do not use 
Rifampicin + boosted PI  Not recommended because of poor pharmacokinetics and 
high rates of hepatotoxicity seen in healthy volunteers 
Rifabutin + unboosted PI  Reduce rifabutin to 150mg daily, increase unboosted PI 
Rifabutin + boosted PI Reduce rifabutin to 150mg three times per week 
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1.6.4 Integrase inhibitors 
Rifampicin + Elvitegravir Do not use 
Rifampicin + Raltegravir* Studies ongoing; use with caution double dose raltegravir  
Rifabutin + Elvitegravir No data, not recommended 
Rifabutin + Raltegravir Normal doses of both drugs 
 
1.6.5 Entry inhibitors 
Rifampicin + Maraviroc* Not recommended, but if given use double dose maraviroc 
Rifabutin + Maraviroc  Use standard doses 
Rifampicin + T-20  No interaction, use standard doses 
Rifabutin + T-20  No interaction, use standard doses 
 
* Where combinations are not recommended, specialist HIV treatment advice should be 
sought. 
 
We recommend that TDM of NNRTI and PI should be performed when drug regimens 
are complex. Drug levels of anti-tuberculosis drugs should be measured when there is 
clinical concern regarding absorption or response to TB therapy. 
 
1.7 Starting HAART 
Starting HAART during TB treatment is complicated by overlapping toxicities, drug 
interactions and immune reconstitution disease, and high pill burdens may reduce 
adherence. Delaying HAART may lead to prolonged or worsening immune suppression. 
Physicians have to balance these risks when deciding when to initiate HAART. Recent 
data suggest early treatment reduces morbidity and mortality. 
 
We recommend, where possible: 
CD4 consistently >350 cells/μL: At physician discretion; CD4 100–350 cells/μL: As soon 
as practical, but can wait until after completing 2 months TB treatment, especially when 
there are difficulties with drug interactions, adherence and toxicities; CD4 <100 cells/μL: 
start HAART as soon as practical after starting TB therapy. 
See BHIVA HIV treatment guidelines for details on starting HAART [3]. 
 
 
1.8 Directly Observed Therapy (DOT) strategies 
DOT is regarded as the gold standard for delivering TB treatment, but it may not be 
possible to deliver all elements of the DOT package. Witnessed supervision of treatment 
may be impracticable and it is important to remember that patient-centred management 
is the cornerstone of treatment success. We recommend that DOT be used in all cases 
of multi-drug resistant TB. 
   
 
1.9 Relapse and treatment failure 
Patients with TB, with or without HIV infection, who are failing treatment or who relapse 
despite therapy pose particular management problems and should be referred to clinical 
colleagues who have expertise in the management of relapse and treatment failure.  
 
1.10 Control and prevention of TB 
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Every hospital/trust should have a policy for the control and prevention of TB. Specific 
consideration should be given to prevention of transmission of TB to and from 
immunosuppressed patients. Further guidance is contained in [4].  
 
2.0 Introduction 
 
Worldwide, it is estimated that 14.8% of all new TB cases in adults are attributable to 
HIV infection. This proportion is much greater in Africa, where 79% of all TB/HIV 
coinfections are found. In 2007, 456 000 people globally died of HIV-associated TB [5].  
All patients with TB, regardless of their perceived risk of HIV infection, should be offered 
an HIV test. In the UK, an increasing number of TB cases are coinfected with HIV. In 
2003, 8.3% of adults with TB were HIV infected [6]. The proportion is higher in London, 
with coinfection rates of 17–25% [7]. 
In HIV coinfection the clinical and radiographic presentation of TB may be atypical. 
Compared to the immune-competent population, TB/HIV patients with active pulmonary 
TB are more likely to have normal chest radiographs or to have sputum which is smear 
negative but culture positive [8–10]. The clinician caring for HIV-infected patients 
therefore needs to have a high index of suspicion for TB in symptomatic individuals, 
especially those born abroad. As the investigation and treatment of both TB and HIV 
require specialist knowledge, it is mandatory to involve specialists in HIV, respiratory 
and/or infectious diseases. 
These guidelines update the BHIVA guidelines from 2005 and are designed to provide a 
clinical framework applicable to adults in the UK coinfected with HIV and TB. These 
guidelines do not cover children. They do not provide advice on HIV testing in adults with 
newly diagnosed TB. They are based on the evidence available, but some 
recommendations have to rely on expert opinion until further data are published.  
 
These guidelines should be used in conjunction with: 
 National Institute for Health and Clinical Excellence. Tuberculosis: clinical 
diagnosis and management of tuberculosis, and measures for its prevention and 
control, 2006 [1].  
 BHIVA guidelines (www.bhiva.org/cms1222226.asp): Treatment of HIV-infected 
adults with antiretroviral therapy (2008).[3] 
 Department of Health. The Interdepartmental Working Group on Tuberculosis. 
The Prevention and Control of Tuberculosis in the United Kingdom, 1998 [4]. 
 National Institute for Health and Clinical Excellence. Tuberculosis: clinical 
diagnosis and management of tuberculosis, and measures for its prevention and 
control, update 2010 [11]. 
 
 
3.0 Aims of TB treatment 
Treatment of TB benefits the individual and also the community. 
The aim of treatment is: 
 to cure the patient of TB; 
 to minimize the transmission of Mycobacterium tuberculosis to other individuals; 
 to eliminate MTB infection. 
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4.0 Diagnostic tests 
The quality of any investigation is related to the quality of the specimen and the clinical 
detail provided within the request. There must therefore be close liaison with the 
mycobacterial laboratory.  
 
4.1 Microscopic smears 
Microscopic smears of body fluids remain an essential part of TB diagnosis. Results 
should be available within 1 working day. 
 
4.2 Cultures and drug susceptibility tests 
Identification of mycobacteria is performed at reference centres, and is based on 
morphology, growth and biochemical characteristics. M. tuberculosis needs to be 
distinguished from other mycobacteria, for which treatment may be different and there 
are no infection control concerns. 
 
Cultures are central to the confirmation and identification of the mycobacterium, and for 
drug susceptibility testing. More rapid results are obtained from liquid media, which 
usually grow M. tuberculosis in 7 to 28 days. Drug susceptibility tests are usually 
available within 10–21 days of the laboratory receipt of isolates and are performed by 
standard assays.  
 
4.3 Molecular methods 
When it is important to differentiate rapidly, gene probes are increasingly used in some 
laboratories, but are less sensitive than culture and are used mainly on respiratory 
specimens. Most nucleic acid amplification methods to detect Mycobacterium 
tuberculosis are complex, labour-intensive, and technically challenging. The sensitivity 
and specificity estimates of commercial NAATs are highly variable, compared with 
culture [12,13].  
 
All specimens, even those negative for M. tuberculosis on PCR, still require culture 
because a negative PCR does not exclude TB and a positive PCR does not indicate the 
drug susceptibility profile [14,15]. However, recently a fully automated molecular test for 
tuberculosis identification and drug resistance testing has been evaluated on sputum 
samples from adult TB or MDRTB [16]. 
 
The Xpert MTB/ RIF, an automated molecular test for MTB identification and resistance 
to rifampin, uses a hemi-nested real-time PCR assay. This assay identifies more 
than 97% of all patients with culture-confirmed tuberculosis, including more than 90% of 
patients with smear-negative disease. The result can be available in hours.  
The assay has been developed as a laboratory-based and point-of-care test for 
developing countries, but may be useful in rapid diagnosis of TB in the UK. Currently 
there are no data derived from children or using non-respiratory specimens in HIV-
infected persons. 
 
Molecular tests for rifampicin resistance are useful especially when MDRTB is 
suspected, as about 95% of isolates which are rifampicin resistant will also be isoniazid 
resistant. As MDR-TB is defined as TB resistant to at least rifampicin and isoniazid, 
patients with positive molecular based rifampicin resistance should be treated as MDR-
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TB until the full resistance profile from cultures is available. 
.  
 
4.4 Tuberculin skin testing 
Tuberculin testing can identify patients with latent infection but there are high false-
negative rates in HIV-positive patients, especially in those at low CD4 cell counts [17–
23]. In patients with AIDS or CD4 <200 cells/μL, the sensitivity of the test is only 0–20%. 
False positives occur after bacillus Calmette–Guèrin (BCG) immunization. Some data 
suggest combining Interferon-γ release assays and tuberculin testing improve sensitivity 
[1,24]. We do not recommend the routine use of tuberculin skin tests. [CII] 
 
4.5 Interferon-γ tests  
HIV-infected individuals with latent TB infection are much more likely to progress to 
active TB than HIV-uninfected people [25]. Detection and treatment of latent TB infection 
is therefore important.  
Blood tests are available that measure Interferon-γ release from T cells after stimulation 
with antigens largely specific to M. tuberculosis (such as ESAT-6 and CFP-10) [26]. The 
current commercially available tests are T-Spot.TB (which uses Elispot technology to 
detect the antigen specific T cells) and QuantiFERON® Gold In-Tube (an ELISA). Both 
tests are approved for the diagnosis of latent TB infection in HIV-negative individuals. 
There are some differences between the two tests, although in general they are 
unaffected by previous BCG and/or infection with most other mycobacteria (an important 
exception in the UK being M. kansasii). They are not licensed for the diagnosis of active 
TB, though the tests may be positive here too (as they detect the host immune response 
to mycobacterial infection). 
 
Limited data exist regarding their performance in HIV infection, but studies suggest that 
Interferon-γ assays are more specific than tuberculin skin tests, especially in BCG-
vaccinated subjects [27–31].This is an area of ongoing research. 
 
They also appear to retain sensitivity more reliably at lower CD4 cell counts, although 
the lower threshold has not yet been defined [32,33]. Their advantages also include 
being a single blood test with no need for patient recall to “read” the result and no 
requirement for cold-chain storage. However the blood samples need processing within 
a limited time, and “indeterminate” (i.e. uninterpretable) IGRA results are more common 
in HIV-infected subjects. They are also more costly than tuberculin tests, though this 
may be offset by the savings in, for instance, healthcare worker time [34].The T-spot.TB 
test may have an advantage over the QuantiFERON® Gold In-Tube test as the number 
of lymphocytes used in the test is standardized. 
 
This is a rapidly developing area but, based on current data, we suggest that IGRA 
rather than TSTs are used when screening HIV-positive individuals for latent TB 
infection. [BIII] 
Where a patient is considered to have active tuberculosis, IGRA tests should not be 
used as the means by which the diagnosis is confirmed or refuted. If a test is performed, 
the result must be interpreted in light of the clinical picture, microbiological data and an 
understanding of the assay’s limitations in this population. 
 
5.0 Type and duration of TB treatment 
 9 
 
5.1 Treatment regimens 
Most adults with previously untreated TB are given a regimen in two phases: [AII] 
 Initial phase 
2 months of isoniazid, rifampicin, pyrazinamide and ethambutol.  
These 4 drugs are necessary because of the relatively high rates of isoniazid 
resistance in the UK, which is 7.7% overall (HPA 2007), and higher in non-white 
ethnic groups and those with previous treatment.  
If drug sensitivity testing shows MTB sensitive to first line agents, ethambutol can 
be omitted. 
 Continuation phase 
4 months of isoniazid and rifampicin in most patients with drug-sensitive TB, 
prolonged to 7 months in some circumstances (see 5.2).  
All patients taking isoniazid should be prescribed pyridoxine (vitamin B6) 10–25mg daily. 
TB therapy can be given five times per week with standard doses. Although there are no 
formal clinical trial data, considerable clinical experience suggests that five-times-weekly 
Directly Observed Therapy (DOT) is equivalent to seven-times-weekly treatment, and 
can thus be considered as “daily”. [AIII] 
 
 
5.1.1 TB or other mycobacterial infection? 
 
In many cases the treatment conundrum is whether the patient has M. avium complex or 
M. tuberculosis and often the physician will give the standard four-drug regimen until 
identification. In this situation some physicians prefer to replace rifampicin with rifabutin 
and add azithromycin/clarithromycin. When non-tuberculous mycobacteria are identified 
the regimen can be modified appropriately. 
 
5.2 Longer continuation phase [AII] 
The continuation phase should be extended to 7 months in: 
 patients with drug-sensitive TB whose initial phase did not include pyrazinamide; 
 patients with cavitating pulmonary disease or who remain sputum culture positive 
after 2 months of treatment [35]. 
 
The total treatment duration would thus be 9 months. 
The continuation phase should be extended to 7–10 months in cases of CNS 
involvement, for instance meningitis or tuberculoma. The total treatment duration would 
thus be at least 9 months. 
 
5.3 Intermittent therapy [AII] 
It is recommended that patients receive daily therapy [36]. However, in some 
circumstances intermittent therapy can be given three times per week with dose 
modification [37,38] but must be by DOT, as one study showed a risk of acquired 
rifamycin resistance in patients given thrice weekly regimens ([DII]). However, DOT was 
used for all doses during the intensive phase but only for one dose of three per week 
during the continuation phase [39].  
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Two strategies used in HIV-negative patients have been associated with unacceptably 
high relapse rates and acquired rifampicin resistance in HIV-infected patients and are 
not appropriate for use in this population [40–44]. [EII] 
These are: 
 once-weekly isoniazid-rifapentine in the continuation phase;  
 twice weekly isoniazid-rifampicin or isoniazid-rifabutin in patients with CD4 
counts <100 cells/μL 
 
5.4 Use of rifabutin [BII] [45] 
Rifabutin has been successfully used instead of rifampicin in treating TB in HIV-negative 
patients [46,47]. It can be regarded as an alternative in HIV-positive patients, especially 
to avoid drug interactions with rifampicin, for example with protease inhibitors (see 6.0). 
Rifabutin showed similar efficacy to rifampicin in a single-blind randomised study of 50 
HIV-positive patients in Uganda [48] and a cohort of 25 patients in the US [49]. 
However, there is a paucity of long-term data with rifabutin in HIV-positive adults. 
Rifabutin is also expensive and toxicities include bone marrow suppression, uveitis and 
arthralgia.  
We therefore recommend that rifampicin remains the drug of choice whenever possible. 
In circumstances where rifampicin cannot be used (most commonly when boosted PIs 
are needed to treat HIV), rifabutin should be substituted. 
 
5.5 Use of rifapentine [EII] 
Rifapentine has a long serum half-life which theoretically allows once-weekly dosing. 
However, in the initial phase of treatment of TB in HIV-negative patients, rifapentine has 
unacceptable 2-year microbiological relapse rates and is not recommended 
Development of rifapentine resistance appears more frequent in TB/HIV coinfected 
patients [42] and at present rifapentine cannot be recommended and should not be 
used. [EII] There are few data regarding the interactions of rifapentine with HAART. 
 
5.6 Duration and effectiveness of TB treatment 
The optimal length of TB treatment in patients coinfected with HIV is unknown. Some 
trials suggest that short-course therapy need not be prolonged in HIV [37,50,51]. A 
review of six studies of patients with HIV infection and three studies of patients without 
HIV infection given treatment for 6 months (or longer) demonstrated considerable 
variability in published study design, eligibility criteria, site of disease, frequency and 
method of dosing, and outcome definitions [52]. In the reported studies, HIV-infected 
patients had cure rates of 59–97%, successful treatment rates of 34–100% and relapse 
rates of 0–10%. In patients without HIV infection, cure rates were 62–88%, successful 
treatment occurred in 91–99% and relapse rates were 0–3%. Although the relapse rates 
appeared higher in some studies of coinfected patients, other outcomes were 
comparable when 6-month regimens were used. 
A study from Brazil showed that tuberculosis recurrence rates were high in the HIV-
infected population but that if there was completion of initial tuberculosis therapy, use of 
antiretroviral therapy, and subsequent increases in CD4 cell counts then recurrence 
rates were low [53].  
A recent retrospective review from the US suggested that although there were no 
failures in the 6 month regimen, relapse rates are four-times higher in HIV patients 
treated with standard rifampicin-based regimens for 6 months than in those treated for 
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longer [36].. However, the data were generated from a relatively small subset of patients 
as only 17% of the HIV-positive patients and 37% of the HIV-uninfected/unknown group 
were given just 6 months of rifampicin-based therapy. DOT was given to 57% of the 
cases. It may be the case that where adherence is suboptimal, 6 months of therapy is 
insufficient. The other important fact is that in this study re-infection could not be 
distinguished from relapse. 
A recent meta analysis suggests 8 months of a rifamycin based treatment be given but 
the studies examined included those in which only 2 months of a rifamycin were given 
and in the few studies of treatment longer than 6 months the reinfection issue was not 
addressed [54]. 
 
Long-term randomised trials are needed to address optimal treatment duration.  
We recommend that for drug-sensitive TB, not involving the CNS, regimens of 6 months 
should be given [41,50,51,55,56]. These should include at least 182 doses of isoniazid 
and rifampicin, and 56 doses of pyrazinamide (see 5.8). [AII] See also sections 5.3 and 
5.4. 
 
5.7 Use of corticosteroids 
 
In HIV-infected adults with pulmonary or pleural TB, corticosteroids do not improve 
survival or reduce TB recurrence [57,58] and are not generally recommended [59]. 
In the general population, NICE guidelines recommend steroids in cases of active 
meningeal or spinal cord TB [1]. At present there is insufficient evidence regarding their 
use in HIV-infected people. A randomised controlled trial in Vietnam showed no 
difference in mortality or a combined outcome of death and disability in HIV-infected 
people with a clinical diagnosis of tuberculosis meningitis, whether they were given 
dexamethasone or placebo with standard TB treatment [60]. However, there were few 
HIV-infected people in this study and the diagnosis of TB was confirmed 
microbiologically in fewer than 50% of cases. This study may therefore have missed a 
clinically important difference.  
Until more data are available we recommend that HIV-infected adults with meningeal or 
spinal cord TB should be given corticosteroids. [BII]  
NICE guidelines recommend steroids for active pericardial TB. There are limited data to 
support this in HIV coinfection. A small randomised controlled trial of HIV-infected adults 
with presumed tuberculous pericarditis treated with standard TB therapy found that 
prednisolone resulted in better outcomes than placebo [61]. Mortality was reduced with 
prednisolone compared to placebo, and improvement in raised venous pressure, 
hepatomegaly, ascites and physical activity occurred more rapidly. Interestingly there 
was no faster resolution of pericardial fluid on chest radiography or echocardiogram, and 
since only 38% had positive M. tuberculosis cultures, some of the subjects may not have 
had pericardial TB. These results should therefore be interpreted with caution. 
Until more data are available in HIV-positive patients we recommend that adults with 
pericardial TB should be given corticosteroids. [AII]  
Other uses of steroids have included preventing ureteric stenosis in renal TB or 
enlargement of, for example, a mediastinal lymph node causing collapse of a lung lobe 
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and in management of TB-related immune reconstitution inflammatory syndrome (see 
section 10) . 
The optimal dose of adjunctive corticosteroids is not known. Rifampicin induces the liver 
metabolism of corticosteroids, thus increasing their plasma clearance [62]. 
 
The corticosteroid and dose used in most adult trials of TB meningitis is dexamethasone 
12–16 mg/day given intravenously until the patient starts taking medicines orally; then 
tablets can be used. Prednisolone 60 mg/day for three weeks and tapered over the next 
three weeks is an alternative [63].  
 
The British Infection Society guidelines on TB meningitis [2] suggest that adults (>14 
years) should start treatment with dexamethasone 0.4 mg/kg/24 hours with a reducing 
course over 6 to 8 weeks. This works out to be a higher dose for most patients seen in 
the UK. 
 
Studies have shown that corticosteroids increase the risk of high blood pressure, raised 
blood glucose and cause fluid retention [57,58]. The risk of infectious complications does 
not seem to be increased [57,58,61], although the data for an increase in the occurrence 
of Kaposi’s sarcoma are contradictory.  
 
5.8 Definition of completion of TB therapy 
Treatment for a defined number of days without accounting for the number of doses 
taken may result in under-treatment. Determination of whether or not treatment has been 
completed should therefore be based on total number of doses taken as well as duration 
of therapy. For example: 
 A 6-month daily regimen (given 7 days/week) should consist of at least 182 
doses of isoniazid and rifampicin, and 56 doses of pyrazinamide.  
 
It is recommended that all of the doses for the initial phase be taken within 3 months and 
those for the 4-month continuation phase be taken within 6 months. The 6-month 
regimen should therefore be completed by 9 months. 
 
5.9 Interruptions of therapy [AIII] 
Treatment interruptions are common in HIV-associated tuberculosis. Data to support 
recommendations are scant. Regardless of the timing and duration of the interruption, if 
the patient was on self-supervised therapy, then DOT should subsequently be used. If 
the patient was already being managed with DOT, additional measures may be 
necessary to ensure adherence, for instance provision of transport, food, social services. 
The CDC suggest the following [64]: 
 
Initial phase: 
 If the interruption occurs during the initial phase and is 14 days or more in 
duration, treatment should be restarted from the beginning. 
 If the interruption is less than 14 days, the treatment regimen should be 
continued. The total number of doses for the initial phase should be given. 
 
5.10 Investigations during TB treatment [AIII] 
Baseline investigations: 
 CD4 count and percentage; 
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 serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) 
bilirubin and alkaline phosphatase; 
 serum creatinine and estimated glomerular filtration rate; 
 platelet count; 
 hepatitis B and C serology; 
 prior to ethambutol: testing of visual acuity with Snellen chart and colour 
vision with Ishihara plates. 
HIV patients have more drug reactions especially those with low CD4 counts. Further 
they may be starting concomitant antiretroviral and other therapies, all of which may 
cause hepatotoxicity. We recommend that liver function tests should be rechecked at 1–
2 weeks even if asymptomatic. Patients with pre-existing liver disease need close 
monitoring, for instance every 2 weeks for first 2 months. 
Most physicians will see the patient 2 weeks after starting antituberculosis therapy and 
then monthly until stable and 1–2 monthly until therapy has been completed. The role of 
a TB specialist nurse and multidisciplinary team is essential in the management of 
coinfected patients. 
In patients with pulmonary TB who still have a productive cough after 2 months, therapy 
should have a repeat sputum smear and culture. The initial phase of treatment should be 
continued until results are available. 
 
 
6.0 Drug–drug interactions (see Tables 4–7) 
Most interactions between HIV and TB therapy are through induction or 
inhibition of metabolic enzymes in the liver and intestine. The most 
important family of enzymes is cytochrome P450 (CYP450). The CYP3A4 
isoform metabolizes many drugs including protease inhibitors (PIs) and non-
nucleoside reverse transcriptase inhibitors (NNRTIs). Rifamycins are potent 
inducers of CYP3A4 65,66and have clinically important interactions with 
PIs and NNRTIs. Rifampicin is the most powerful inducer of CYP3A4 of all 
medicines. Rifapentine is a less potent inducer; and rifabutin much less so. 
To a smaller extent, rifampicin also induces the activity of CYP2C19 and CYPD6. 
Rifampicin also increases activity of the intestinal drug transporter P-glycoprotein (PgP) 
that contributes to the absorption, distribution and elimination of PIs new 67,68 ref 
67. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, 
pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA 
and oligonucleotide expression arrays  
J Pharmacol Exp Ther. 2001;299):849- 57.  
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68.Li T, Chiang JY.  Rifampicin induction of CYP3A4 requires pregnane X receptor 
cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of 
small heterodimer partner gene expression. Drug Metab Dispos. 2006;34):756-64.  
 
 
 
 
The enzyme inducing effect of rifampicin takes at least 2 weeks to become maximal and 
persists for at least 2 weeks after rifampicin has been stopped. If antiretrovirals are 
started or changed at the end of TB treatment this persistent effect on enzyme induction 
should be taken into consideration.  
 
Rifabutin is a less potent inducer of CYP3A4 than rifampicin [69]. Unlike rifampicin, it is 
also a substrate of the enzyme [65]. Any CYP3A4 inhibitors will therefore increase the 
concentration of rifabutin although they have no effect on rifampicin metabolism. Most 
PIs are inhibitors of CYP3A4 and when used with rifabutin, plasma concentrations of 
rifabutin and its metabolites may increase and cause toxicity [70]. 
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are mostly known to be 
free of clinically significant interactions with rifampicin. In theory they should not have 
significant interactions with other first line antituberculosis therapies. Few data are 
available for the newer antiretroviral agents. The CCR5-inhibitor maraviroc interacts with 
rifamycins, as do the integrase inhibitors raltegravir and elvitegravir.  
Individual drug–drug interactions between rifamycins and antiretroviral agents are shown 
in Tables 4–7. The complexity of drug–drug interactions requires expertise in use of both 
antiretroviral and anti-TB drugs. One particular interaction should be noted: the 
metabolism of corticosteroids (e.g. prednisolone) is accelerated by rifamycins and higher 
doses are needed. The dose of steroid should be increased by around 50% with 
rifampicin and 33% with rifabutin. [AII] 
 
6.1 Rifamycins and NRTIs (Table 4) 
When NRTIs are given with rifampicin either the pharmacokinetics change little, or the 
interactions are unknown. Rifampicin reduces the AUC and increases the clearance of 
zidovudine via increased glucuronidation [71]. This is not clinically significant and dose 
alteration is not required. Rifabutin does not affect the clearance of zidovudine [72]. 
Triple-NRTI regimens are theoretically attractive as HAART because they are free of 
interactions with TB treatment, and have been used with success in Africa [73,74]. 
However, they are virologically inferior to HAART containing an NNRTI [75]. Quadruple-
NRTI regimens (most commonly abacavir, lamivudine, zidovudine, tenofovir) have also 
been used in adults taking TB treatment. There are data from a small cohort to support 
this approach [76], but it is not recommended as standard of care in the UK. 
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6.2 Rifamycins and NNRTIs (Table 5) 
Efavirenz, nevirapine, etravirine and the newer agent rilpivirine are substrates for, and 
inducers of, CYP3A4. The clinical use of these drugs together with rifamycins is 
complex.  
 
6.2.1 Rifampicin and efavirenz 
There is still debate regarding the appropriate dose of efavirenz with rifampicin. Several 
studies have found a 20–30% reduction in efavirenz levels when administered with 
rifampicin [77,78]. Increasing the efavirenz dose from 600mg to 800mg is effective and 
safe [77,79]. However, in cohort studies (in which most of the participants have an 
average low body weight) standard dose efavirenz has been given with rifampicin 
without lower drug exposure or compromised clinical efficacy [80,81]. In one study, 
efavirenz levels were not predicted by weight or gender and were not associated with 
HIV clinical outcomes – even though half the cohort had concentrations below the 
expected therapeutic range (1000–4000 ng/mL). This, as well as other studies, confirms 
the large interpatient variability in efavirenz levels [82]. No randomised clinical trial data 
has correlated patient weight, pharmacokinetics and clinical outcome. One observational 
cohort has examined PK and outcomes and weight and proposed that for patients >60kg 
a dose of 800mg efavirenz.should be used if the patient is on rifampicin [83].  
It is therefore difficult to make recommendations for patients in the UK where body 
weights are usually >60kg. In fact, in one study no difference in mid-dose efavirenz 
levels between patients on efavirenz 800mg/d (n=31) and those on efavirenz 600mg/d 
(n=29) were seen in a cohort of black South Africans on rifampicin-based TB therapy 
[84]. This may be explained by the high rate of polymorphisms in CYP450 2B6 in black 
Africans, present in 20% of the black population compared with 3% of whites [85,86]. 
The use of 800mg may increase the risk of CNS side effects, especially in individuals 
with polymorphisms in CYP2B6, and this may explain high rates of clinical toxicity in 
some studies [87]. If side effects occur, TDM can identify those individuals with high 
efavirenz levels.  
We recommend that when rifampicin is used with efavirenz in patients over 60kg, the 
efavirenz dose is increased to 800mg daily. Standard doses of efavirenz are 
recommended if the patient weighs less than 60kg. [AII] We then suggest that a TDM be 
performed at around week 2 of starting efavirenz and the dose adjusted accordingly. It 
should be made clear to patients that they need to have an extra 200mg efavirenz in 
addition to the Atripla. Some physicians prefer to start with 600mg efavirenz whatever 
the body weight and perform TDM and adjust the dose accordingly. We believe, 
however, that the risk of toxicity is more easily solved than the risk of potentially inducing 
resistance from inadequate drug levels. 
 
6.2.2 Rifampicin and nevirapine 
Rifampicin and nevirapine are both used widely in resource-poor countries because they 
are cheap and readily available. There are data that nevirapine levels are reduced by 
20–55% by rifampicin [88–93]. WHO suggest that no ‘lead in’ period for nevirapine is 
needed if the patient is already on rifampicin – but they give no recommendation rating 
for this strategy. 
 
To overcome the problem of low nevirapine levels with rifampicin, one trial administered 
400mg nevirapine as lead-in dose, increasing to 600mg [94]. The pharmacokinetics 
were satisfactory but there was a high incidence of nevirapine hypersensitivity during the 
dose escalation period. 
 1
6 
Two cohort studies have shown high rates of HIV viral suppression with standard dose 
nevirapine and rifampicin [89,95]. However, in a recent study of 1283 patients starting 
HAART while on rifampicin, 209 people on nevirapine and 1074 on efavirenz, virological 
failure rates were higher, with an OR (CI) of 2.9 (1.8–4.7) in the nevirapine arm vs. the 
efavirenz or not-on-TB-treatment arms [96]. 
We recommend that, where alternatives exist, rifampicin should not be used with 
nevirapine. [DII] If there are no alternatives to using nevirapine with rifampicin, then 
normal doses should be used and therapeutic drug monitoring performed.  
 
6.2.3 Rifampicin and etravirine 
No data are available and no studies are planned. It is thought that they should not be 
co-administered. 
 
6.2.4 Rifampicin and rilpivirine (TMC-278) 
Rifampicin reduces plasma concentrations of TMC-278 by up to 90% so these drugs 
should not be used together [97].  
 
6.2.5 Rifabutin and NNRTIs 
If rifabutin is used with efavirenz the rifabutin dose should be increased to 450mg daily 
because of the induction effect of efavirenz, which reduced the AUC of rifabutin by 38% 
in one small study.  
 
Concomitant administration of nevirapine results in increased rifabutin AUC (17%) and 
Cmax (28%) with no change in Cmin. The effect on nevirapine pharmacokinetics was not 
significant (Viramune SPC 2007). Due to high intersubject variability, some patients may 
be at risk of rifabutin toxicity. Rifabutin and nevirapine can probably be given together 
with no adjustment in either of their dosages but more data are needed before this 
strategy can be recommended.  
 
Rifabutin can be given with etravirine with no dose adjustments.  
 
Rifabutin decreases plasma levels of rilpivirine by 50%, so if used together the dose of 
rilpivirine should be doubled [97].  
 
6.3 Rifamycins and Protease Inhibitors (PIs)  
In general Protese inhibitors whether boosted or unboosted should not be given 
with rifampicin and rifabutin should be considered instead. 
6.3.1 Rifampicin and PIs (Table 6) 
 
6.3.1.1 Unboosted PIs 
Rifampicin causes a 75–95% reduction in plasma concentrations of PIs other than 
ritonavir [98]. Such reductions lead to loss of antiretroviral activity of PI-containing 
regimens and can result in the emergence of antiretroviral resistance. 
Since ritonavir is itself an inhibitor of CYP3A4 it can be used in combination with 
rifampicin when given at full dose of 600mg twice daily [99]. However such high dose 
ritonavir is very poorly tolerated and seldom used [100].  
 
6.3.1.2 Boosted PIs 
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Most patients are given PIs with low dose ritonavir (100mg or 200mg daily) to take 
advantage of its enzyme-inhibiting properties. Ritonavir boosts the concentration of the 
other PI allowing more tolerable dosing.  
 
6.3.1.3 Saquinavir/ritonavir 
A dose of twice-daily 400mg ritonavir with 400mg saquinavir has been used with 
rifampicin with acceptable PI pharmacokinetics [101]. Saquinavir 1600mg with ritonavir 
200mg once daily was tested in HIV-positive patients on rifampicin-based TB therapy, 
and saquinavir levels were inadequate [102,103].  
 
A pharmacokinetic study performed in healthy volunteers given saquinavir/ritonavir and 
rifampicin then demonstrated severe hepatotoxicity [104]. Transaminases were elevated 
to more than 20-times upper limit of normal.  
 
Saquinavir/ritonavir is therefore not recommended in combination with rifampicin. 
 
6.3.1.4 Lopinavir/ritonavir 
Data regarding the interaction of rifampicin with standard-dose lopinavir/ritonavir suggest 
that ritonavir at low dose does not compensate for the inducing effect of rifampicin on 
lopinavir metabolism [105]. A popular strategy in the developing world for patients with 
NNRTI failure who develop TB, is to give lopinavir/ritonavir with increased-dose ritonavir. 
If the ritonavir dose was increased to 400mg twice daily then lopinavir trough 
concentrations were adequate in 9/10 subjects but there were high rates of elevated 
transaminases and lipids, and gastrointestinal toxicity [106]. A pharmacokinetic study in 
healthy volunteers was reminiscent of the saquinavir study, and was terminated early 
because of high rates of severe transaminitis [107]. 
 
6.3.1.5 Atazanavir/ritonavir 
Recent data suggest that atazanavir with or without ritonavir boosting had unfavourable 
pharmacokinetics when administered with rifampicin [108–110]. Trough atazanavir 
concentrations were reduced by >80% [109]. 
 
6.3.1.6 Tipranavir/ritonavir 
Tipranavir concentrations were reduced by 80% by rifampicin [111]. 
 
6.3.1.7 Darunavir/ritonavir 
The interaction between darunavir and rifampicin has not yet been investigated. In line 
with other PIs, it is currently recommended that darunavir should not be coadministered 
with rifampicin.  
 
6.3.2 Rifabutin and PIs (Table 6) 
 
6.3.2.1 Unboosted PIs 
The use of rifabutin in treating TB in HIV-positive patients is discussed above (see 5.5). 
Rifabutin can be administered with unboosted PIs except saquinavir [112], although they 
will rarely be used in practice. The balance between rifabutin induction and PI inhibition 
of CYP3A4 means that the dose of rifabutin should be decreased from 300mg to 150mg 
daily to avoid toxicity [48,70]. 
 
6.3.2.2 Boosted PIs 
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If PIs are used with low-dose ritonavir boosting then the dose of rifabutin should be 
reduced to 150mg three times per week [49,111]. This data has been extrapolated from 
PK studies in healthy volunteers and modelling. There are no clinical outcome data for 
either HIV or tuberculosis using this strategy. Adherence should be monitored closely as 
the dose of rifabutin would become inadequate if the boosted PI is not taken 
concomitantly. Where available, drug levels of the protease inhibitor should be 
measured. There have been reports of acquired rifabutin resistance occurring even 
using rifabutin 150mg three times a week with boosted PIs. No rifabutin drug levels were 
available in those patients and although other reasons may have been responsible for 
these failures physicians may consider measuring rifabutin and its active metabolite 25-
0-desacetyl rifabutin levels if results are available in a timely manner [113]. 
Complex interactions may occur when a rifamycin is given with salvage regimens such 
as two PIs plus boosted ritonavir, or with a boosted or non-boosted PI and an NNRTI. 
Rifabutin is safer than rifampicin, but there are few data to guide the clinician regarding 
dose modification. TDM is recommended. 
 
6.3.3 Recommendation for rifamycins and boosted protease inhibitors 
We recommend that PI/ritonavir combinations should not be given with rifampicin. [EII] If 
possible the HAART regimen should be changed to avoid PIs. If effective HAART 
necessitates the use of PIs then rifabutin should be used instead of rifampicin. [AII] 
  
6.4 Rifamycins and Integrase Inhibitors (Table 7) 
Raltegravir is metabolized by UGT1A1 glucuronidation. Rifampicin is an inducer of 
UGT1A1, and reduces trough levels of raltegravir by approximately 60% [114]. Because 
the antiviral activity of raltegravir 200mg twice daily was very similar to that of the 
licensed dose (400mg twice daily) an earlier recommendation was that standard doses 
of raltegravir should be used with rifampicin. There is at least one report of raltegravir 
failure when given like this with rifampicin (S Taylor, personal communication). 
Further PK studies show that even with double-dose raltegravir at 800mg bd the Ctrough of 
raltegravir is at the lower level of what has been observed in clinical studies of raltegravir 
without rifampicin [115]. It appears for raltegravir that the important PK parameter is the 
AUC24 rather than the Ctrough in PK/PD studies and thus 800mg bd may be adequate. 
As there is little clinical experience with this dose in combination coadministration should 
probably be avoided if alternatives exist.  
Elvitegravir is metabolized by CYP3A4 and should not be given with rifampicin.  
The data regarding interactions with rifabutin.suggest normal doses of raltegravir and 
rifabutin can be used [116].   
 
6.5 Rifamycins and CCR5-antagonists (Table 7) 
Maraviroc is metabolized by CYP3A4 and its levels are reduced by rifampicin. Use of 
maraviroc with rifampicin is not recommended especially if a second enzyme inducer 
such as efavirenz is used. If they are used together then they should be used with 
caution and the dose of MVC be doubled to 600mg bd [117]. There are no data about 
interactions with rifabutin but maraviroc concentrations are predicted to be adequate, 
and maraviroc can therefore be given at standard doses with rifabutin.  
 
6.6 Rifamycins and enfuvirtide (Table 7) 
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There are no significant interactions between rifamycins and enfuvirtide [118]. 
 
6.7 Isoniazid  
Pharmacokinetic or clinical interactions between isoniazid and antiretroviral agents have 
not been extensively investigated. In vitro studies have shown that isoniazid is a weak 
inhibitor of CYP3A4 [119,120]. When given together with rifampicin (inducer), the 
inhibition effect of isoniazid is masked.  
 
   
   
 
6.8 Non-rifamycin regimens 
HIV-related tuberculosis may be treated with non-rifamycin-containing regimens but 
these are inferior in efficacy, with high relapse rates [121,122]. They should only be 
contemplated in patients with serious toxicity to rifamycins, where desensitization or 
reintroduction has failed, or in those with rifamycin-resistant isolates.There has been a 
review published of drug–drug interactions between drugs used in non-rifamycin 
regimens and antiretrovirals [123].  
 
7.0 Overlapping toxicity profiles of antiretrovirals and TB therapy 
Adverse reactions to drugs are common among patients with HIV-related tuberculosis 
especially if taking HAART concomitantly. 
 
Rash, fever and hepatitis are common side effects of anti-tuberculosis drugs especially 
rifampicin, isoniazid and pyrazinamide. NNRTIs and cotrimoxazole cause similar 
adverse reactions. The coadministration of these drugs can lead to difficult clinical 
management decisions if these side effects occur, especially if HAART and TB drugs are 
started concurrently. A total of 167 adverse events were recorded in 99 (54%) of the 183 
patients for whom data on therapy were available in a study from the South East of 
England [124]. Adverse events led to cessation or interruption of either TB or HIV 
therapy in 63 (34%) of the 183 patients. Side effects usually occurred in the first 2 
months of treatment and were peripheral neuropathy 38 patients (21%), rash 31 patients 
(17%), gastrointestinal intolerance 18 patients (10%), hepatitis 11 patients (6%) and 
neurological events in 12 patients (7%). Rifampicin was frequently implicated by the 
treating physicians, and was considered responsible for almost two-thirds of adverse 
events. 
When compared to HIV-negative TB patients, a higher rate of serious (grade III/IV) 
toxicities has been found in TB/HIV coinfection, but there was no difference in 
discontinuation rate of TB medication between the groups [125].  
 
7.1 Hepatotoxicity [126]  
Hepatotoxicity is a common and potentially serious adverse event. It is defined as: 
 serum AST or ALT > 3x upper limit of normal in the presence of symptoms, or 
 serum AST or ALT > 5x upper limit of normal in the absence of symptoms. 
 
Hepatotoxicity may be caused by many drugs used in the treatment of HIV-positive 
patients, for instance azoles, macrolides etc, and not all hepatotoxic reactions are 
always due to antituberculosis therapy. 
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Hepatotoxicity due to isoniazid in the general population increases with age, occurring in 
less than 0.3% of those under 35 years and 2.3% of those over 50 years. It is also more 
likely with heavy alcohol intake, hepatitis C coinfection and in those also on rifampicin. 
High rates of adverse reactions requiring changes in therapy have been reported in HIV-
infected patients who are likely to have some or all of the other risk factors above. The 
rates of adverse reaction were 26% in one HIV cohort compared with 3% in the HIV-
uninfected group, and other studies have shown similar results [127,128]. 
 
Another study showed little increase in hepatotoxicity in HIV-positive patients with TB 
although only 16.3% were receiving antiretrovirals and the study included children [129].  
 
Management of hepatitis: 
I. Stop all potentially hepatotoxic drugs immediately, including isoniazid, rifampicin, 
pyrazinamide, antiretrovirals and co-trimoxazole. 
II. Check serology for hepatitis A, B and C. 
III. Enquire about exposure to other hepatotoxins including alcohol. 
IV. As resolution of the hepatitis may be prolonged and until the cause of the hepatitis 
is identified then it may be necessary to treat with two or more anti-tuberculosis 
medications without significant risk of hepatotoxicity, such as ethambutol, 
streptomycin, amikacin/kanamycin, capreomycin or a fluoroquinolone. (N.B. 
moxifloxacin can cause a severe hepatitis.) 
V. Monitor serum AST (or ALT), bilirubin and symptoms frequently. Once AST drops 
to less than twice the upper limit of normal and symptoms have significantly 
improved, first line medications can be restarted using a reintroduction regimen 
(Table 8). These are based on common practice and have not been formally 
validated in clinical trials. Recent data in HIV-negative/unknown patients suggest 
that once the AST/ALT is <100iu/L then full dose treatment may be reintroduced 
[130] – whether this also applies to HIV co-infected subjects remains unclear. 
 
VI. If the drugs cannot be restarted or the initial reaction was life-threatening then an 
alternative regimen should be used (see 7.2). 
 
7.2 Pre-existing liver disease 
All patients should be screened for active hepatitis B and C. The risk of hepatotoxicity 
with pre-existing liver disease is greatest with pyrazinamide, then isoniazid, and then 
rifampicin. Isoniazid and rifampicin are essential drugs in short-course TB treatment 
regimens and should be used whenever possible, even in the presence of pre-existing 
liver disease.  
In patients with baseline abnormal hepatic transaminases, a rise of two-to-three times 
this abnormal baseline should be used as threshold for hepatoxicity [126]. 
 
 If hepatotoxicity occurs then other regimens can be used, for instance: 
I. Avoid pyrazinamide and treat with isoniazid and rifampicin for 9 months, adding 
ethambutol for the first 8 weeks or until isoniazid and rifampicin susceptibility are 
demonstrated. [AIII] 
II. Avoid isoniazid and treat with rifampicin, ethambutol, and pyrazinamide for 2 
months, followed by 10 months of rifampicin and ethambutol. [BIII] 
III. Use only one potentially hepatotoxic agent in patients with severe liver disease and 
treat with rifampicin plus ethambutol for 12–18 months, preferably with another 
agent such as a fluoroquinolone for the first 2 months. There are no data to support 
this recommendation. [CIII] 
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In patients with pre-existing liver disease, frequent clinical and laboratory monitoring 
should be performed to detect drug-induced hepatic injury. This should include AST (or 
ALT), platelet count and prothrombin time at least 2-weekly initially. Patients should be 
told to report symptoms such as anorexia, nausea, vomiting, abdominal pain or jaundice 
immediately [131,132].  
 
7.3 Gastrointestinal side effects 
Epigastric pain, nausea and vomiting are common especially in the first 2–3 weeks after 
starting anti-tuberculosis therapy. If the patient has no evidence of hepatic disease and 
is unresponsive to symptomatic treatment, for instance with anti-emetics, then they can: 
 take medications with meals (except with doses under 600mg rifampicin 
daily); food delays or decreases the absorption of isoniazid and rifampicin but 
the effect is moderate and of little clinical significance;  
 change the time of dosing; 
 switch to a regimen that does not have food restrictions such as rifabutin, 
ethambutol, pyrazinamide and a fluoroquinolone. 
Patients should avoid dividing doses or changing to alternative drugs if at all possible, 
although dividing the dose, for instance of pyrazinamide, can improve tolerability. 
 
7.4 Peripheral neuropathy 
The nucleoside analogues ddI and d4T cause peripheral neuropathy and there is an 
additive toxicity of isoniazid when used with d4T [124, 133]. In individuals already taking 
these antiretrovirals alternatives should be found if possible. 
Pyridoxine 10mg daily should be used in all patients receiving isoniazid. If peripheral 
neuropathy occurs the dose of pyridoxine can be increased up to 50mg tds. 
 
7.4.1 Recommendation [DII] 
D4T should not be used as part of a HAART regimen if concomitant isoniazid is being 
administered. In patients on HAART coming from resource poor countries where D4T is 
used widely in initial therapy, switching to an alternate nucleoside should be performed. 
 
7.5 Rash 
Rashes are often mild/moderate and usually occur in the first 2 months of treatment. 
They should be managed in a similar way to the management of nevirapine 
hypersensitivity rashes. Mild rashes without mucosal involvement can be treated 
symptomatically. More widespread worsening rashes or those with systemic symptoms 
require all drug cessation, and on recovery careful drug reintroduction as per protocol 
(see Table 8). 
One compounding issue is that patients may have also recently started cotrimoxazole or 
antivirals and so the offending drug can be difficult to track down. 
 
8.0 Drug absorption 
 
8.1 Malabsorption of drugs 
In HIV infection, malabsorption has been reported with all first-line anti-TB drugs, as well 
as ethionamide and cycloserine. Absorption may be decreased in patients with a low 
CD4 cell count because of HIV enteropathy or other HIV-related gut disease. Sub-
therapeutic plasma drug concentrations may cause treatment failure and drug resistance 
[134,135]. Although some studies show lower peak concentrations of rifampicin and 
ethambutol as well as lower AUC compared with controls [136–140], there are other 
data suggesting that rifampicin is well absorbed in HIV patients including those with 
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AIDS or diarrhoea [141]. There are few data showing correlation of treatment failure with 
poor absorption [112]. 
 
 
8.2 Therapeutic drug monitoring (TDM) 
 
8.2.1 TDM of TB drugs: [CII] 
There are few data showing that TDM results in improved outcomes and the use of TDM 
in TB has been reviewed [142]. However it may be considered in the patient populations 
who are:  
• at high risk of malabsorption of TB drugs; 
• responding inadequately to DOT with first-line drugs; 
• being treated for multi-drug resistant TB; 
• on non-standard TB regimens or taking non-standard doses; 
• on boosted PIs with rifabutin 3 times a week. 
 
One of the problems with monitoring anti-TB drugs is that the kinetics of absorption are 
not predictable. It is therefore difficult to know when to measure a peak plasma level, 
and it is probably best to check levels at more than one time point post dose if possible. 
If rifabutin levels are being measured ensure that the level of 25-0-desacetyl rifabutin, 
the active metabolite, is also measured. 
Decisions about dosing may be difficult as there can be long delays in results being 
returned to the physician. 
 
8.2.2 TDM of HIV drugs: [BII] 
TDM may be relevant for PIs and NNRTIs especially when regimens are complex, when 
no formal pharmacokinetic data are available, and when virological failure occurs. 
 
9.0 When to start HAART 
The optimal time to start HAART in TB/HIV patients is not known. Prospective trials are 
underway in developing countries to answer this question [143]. Much data are currently 
in abstract form, from presentation at meetings, and have not yet been subjected to 
formal peer-review. However, given the importance of this area, we have sought to 
provide some pragmatic guidance.  
 
Physicians have to balance the risk of HIV progression against the hazards of starting 
HAART, which include toxicities, side effects, immune reconstitution inflammatory 
syndrome (IRIS) and drug interactions. Antiretroviral and anti-tuberculosis drugs share 
similar routes of metabolism and elimination, and extensive drug interactions may result 
in sub-therapeutic plasma levels of either or both (see 6.0). Overlapping toxicity profiles 
may result in the interruption of TB or HIV regimens with subsequent microbiological or 
virological failure (see 7.0). Deaths in the first month of TB treatment may be due to TB, 
while late deaths in coinfected persons are attributable to HIV disease progression [144–
146]. 
 
Patients with HIV and a CD4 cell count >350 cells/μL have a low risk of HIV disease 
progression or death during the subsequent 6 months of tuberculosis treatment, 
depending on age and viral load [3]. They should have their CD4 cell count monitored 
regularly and antiretroviral therapy can be withheld during the short-course tuberculosis 
treatment. 
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Most patients with tuberculosis in the UK present with a low CD4 count, often <100 
cells/μL. In such patients HAART improves survival, but can be complicated by IRIS and 
drug toxicity. Cohort data showed that at CD4 counts <100 cells/μL the short-term risk of 
developing further AIDS-defining events and death is high, and HAART should be 
started as soon as practicable [124, 147–150 Some physicians prefer to wait for up to 2 
weeks before starting HAART after commencing patients on TB treatment to allow 
diagnosis and management of any early toxicity and adherence problems 
  A randomized trial (the SAPIT study) [151] compared 2 groups starting HAART 
during TB therapy (one group started within 4 wks of starting TB treatment, the 
other started within 4 wks of completing TB treatment intensive phase) to a 
control group who did not start HAART until after completing their TB treatment. 
The data showed that deferring HAART until after TB treatment was completed 
was associated with a significant increase in mortality, even in patients with CD4 
counts of >200 cells/μL, although there were few clinical events. We do not know 
if  the six patients in this SAPIT study who died, out of the 86 who had TB, still  
had CD4 counts >200 cells/μL at the time of death. 
  Further unpublished analyses of this important data set [152]showed that patients 
with CD4 counts <50 cells/μL at enrolment who started within 4 weeks of 
commencing TB treatment was associated with  a 68% lower risk of developing 
further AIDS clinical events and death compared to those with CD4 counts <50 
cells/μLwho did not start HAART. 
 A recent unpublished study from Cambodia suggested that treatment with HAART in the 
first two weeks of TB treatment resulted in a lower mortality rate than in the group 
delaying HAART to 8 weeks The majority of these patients had a CD4 count of <100 
cells/μL at enrolment.[153] 
The unpublished STRIDE (ACTG 5221) Study [154] also showed that starting HAART 
within 2 weeks resulted in a lower mortality rate than in the group delaying HAART until 
8-12 weeks in patients who  had a blood CD4 count of <50 cells/μL at enrolment.[153] 
In these trials the disadvantage of starting early was an increased risk of IRIS.  
Until we have further analyses of all data, we believe it is safer and more practicable to 
set a blood CD4 count of <100 cells/μL as the point below which HAART should be 
started within 2 weeks of commencing TB treatment. 
.  
Other data sets suggest starting HAART early independent of CD4 cell counts improves 
long term outcome [155,156]. Some physicians believe that starting HAART irrespective 
of CD4 cell count, including >350 cells/μL, is beneficial in patients with active 
tuberculosis. Although theSAPIT study suggested HAART started during the course of 
TB therapy even in those with CD4 counts >350 cells/μL was beneficial, almost all the 
patients within this arm had a CD4 count below that threshold. 
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A currently unpublished study of starting HAART early versus late performed in HIV-
associated TB meningitis in the developing world, where 90% were male, the majority 
drug users, many with advanced disease and the diagnosis being made clinically in 
40%, showed no difference in mortality if HAART were started early though there was a 
greater incidence of severe adverse events in the early arm [157]. How this translates to 
UK clinical practice remains unclear. .  
 
9.1 Suggested timing of HAART in TB/ HIV coinfection [AII] 
 
Taking into account all limited data available we recommend:  
 
CD4 count, cells/μL When to start HAART 
<100 As soon as practical 
100–350 As soon as practical, but can wait until after 
completing 2 months TB treatment, 
especially when there are difficulties with 
drug interactions, adherence and toxicities 
  
>350  At physician’s discretion 
 
 
 
 
10.0 Immune reconstitution inflammatory syndrome (IRIS) 
After starting anti-tuberculosis treatment some patients develop an exacerbation of 
symptoms, signs or radiological manifestations of TB. This has been well described in 
patients without HIV infection, but appears to occur more commonly in HIV-positive 
patients [158–177]. The phenomenon is known as immune reconstitution inflammatory 
syndrome (IRIS), immune reconstitution disease (IRD) or paradoxical reaction. 
The aetiology of these reactions is unknown, but they are presumed in HIV disease to 
occur at least in part as a consequence of HAART-related reconstitution of immunity, 
which leads to an abnormal immune response to tubercle antigens released by dead or 
dying bacilli [178–183]. 
10.1 Definition 
IRIS does not have a widely accepted definition although an international attempt has 
been made. A definition for resource-poor countries has been developed and cases 
need to meet three criteria (see Table 10) [184]. 
  
It is characterised by worsening or appearance of new signs, symptoms, or radiographic 
abnormalities, occurring after initiation of HAART, and not the result of TB treatment 
failure or another disease process. It is therefore a diagnosis of exclusion. It is often 
defined as transient but can last many months. It is usually seen when the TB is 
microbiologically controlled but cases can occur with viable organisms isolated on 
culture.  
 
The features of IRIS are: 
• apparent worsening/progression of tuberculosis; 
• may occur at original site of disease or at remote site; 
• may occur at any time after initiation of TB treatment; 
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• associated with commencing or continuing HAART; 
• no evidence of TB relapse or recurrence (positive AAFB smear does not exclude 
diagnosis of IRIS); 
• appropriate investigations have excluded disease due to other pathogens; 
• drug hypersensitivity is excluded; 
• a response to corticosteroids does not confirm diagnosis of IRIS. 
 
10.2 Epidemiology of IRIS 
In the era of HAART, IRIS has been reported widely and occurred in 36% (12/33) and 
32% (6/19) of patients in two studies [168,174]. In another study IRIS was not 
significantly more common in patients receiving HAART (3 of 28 cases or 11%) 
compared with patients not on antiretroviral treatment (3 of 44 cases or 7%) [175]. The 
majority of reactions occur within 60 days of initiating HAART, with a median of 15 days 
[176]. IRIS does not appear to be associated with any particular antiretroviral regimen or 
drug class [185]. Most patients with IRIS have advanced HIV infection (in one study the 
median baseline CD4 count was 35 cells/μL, and median HIV viral load >500,000 
copies/mL). In the recent CAMELIA Trial the risk of IRIS was increased around four-fold 
if HAART were started in the first 2 weeks compared to delaying HAART until  beyond 
week eight of TB treatment [153]. 
With limited data it is difficult to predict risk of IRIS, but the following appear to be 
relevant [152,185–188]. 
 low baseline CD4 cell count; 
 rapid recovery in CD4 numbers; 
 rapid decline in HIV viral load; 
 dissemination of TB outside the lung (may be due to high burden of bacilli); 
 HAART started within first 2 months of TB treatment. 
 
10.3 Clinical features of IRIS 
IRIS most often presents with fever and increased or new lymphadenopathy [158-189]. 
The skin overlying lymph nodes is often inflamed and dusky red, and the nodes can 
spontaneously rupture. New or worsening pulmonary lesions, pleural and pericardial 
effusions, ascites, psoas abscess, cutaneous lesions and new or expanding central 
nervous system tuberculomata, for example, have also been described 
 
10.4 Management of IRIS [AIII] 
TB treatment failure, drug hypersensitivity and other opportunistic infections and 
malignancies need to be excluded.  
 
10.4.1 Corticosteroids [AII] 
The management of IRIS may require moderate to high-dose corticosteroids to control 
symptoms. Prednisone or methylprednisolone have been used at a dose of 1–1.5 mg/kg 
and gradually reduced after 1 to 2 weeks. Patients who have been on rifampicin for 2 
weeks or more will have increased liver metabolism of corticosteroids such that the 
corticosteroid is effectively reduced by 33–50%. Patients may require steroids for 
prolonged periods of time and IRIS may relapse when the dose is reduced, necessitating 
higher doses. Physicians should be aware of the metabolic side effects and potential for 
serious infections, for instance cytomegalovirus retinitis with high dose corticosteroids. 
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A placebo controlled study of giving steroids or placebo in early IRIS showed a benefit 
but the data have to be interpreted with caution as a substantive proportion of the 
placebo arm were treated with open label prednisolone [190]. 
 
10.4.2 Other treatment options 
Recurrent needle aspiration of nodes or abscesses is appropriate if they become tense 
and/or inflamed. This can prevent spontaneous rupture which may lead to long-term 
sinus formation and scarring. 
Other treatments have as yet little evidence supporting their use. Non-steroidal anti-
inflammatory agents are generally not helpful. Temporary discontinuation of antiretroviral 
therapy has also been advocated but can cause precipitous falls in CD4 cell counts. 
Leukotriene overactivity has been implicated in IRIS, and montelukast can be 
considered as an alternative to steroids, but may need to be continued for a long period 
[191]. [DII] 
 
Preliminary data suggest a potential role for IL-2 and granulocyte-macrophage colony 
stimulating factor (GM-CSF) in improving abnormal T cell responses [192]. [DIII] Other 
therapies such as hydroxychloroquine are as yet unproven. There is one case report of 
the resolution of IRIS in an HIV-negative patient with the use of infliximab [193]. [DIII] 
 
 
 
11.0 Directly observed therapy (DOT) 
There have been no randomized controlled trials or systematic reviews into the use of 
DOT in TB/HIV coinfection. However, the use of directly observed therapy is seen as the 
gold standard by WHO and CDC for the treatment of HIV-related tuberculosis, especially 
when using intermittent dosing. It is recommended by NICE for those deemed likely to 
have poor adherence, including those who are street- or shelter-dwelling homeless [1].  
To help prevent the emergence of resistance, combination tablets (e.g. Rifater, which 
includes rifampicin, isoniazid and pyrazinamide) should be used whenever practicable. 
It is recommended that all patients with MDR-TB have DOT. [AII] 
Patient-centred care should be at the core of multidisciplinary management and should 
always include an adherence strategy. This may include DOT/supervised therapy for 
HAART [194]. [BIII] However, there are no published data on the utility and efficacy of 
combined HAART/TB DOT in treating HIV/TB coinfection. 
DOT usually requires that patients be observed to ingest each dose of anti-tuberculosis 
medication. Any treatment plan should be individualized to incorporate measures that 
facilitate adherence. These may include social service support, treatment incentives, 
housing assistance, referral for treatment of substance misuse, and co-ordination of 
tuberculosis services with those of other providers. There are many patients taking both 
HIV and TB therapies concomitantly. A maximum adherence model which is patient-
centred, and utilizes family and friends and other social support as well as health care 
workers to ensure adherence, is an approach being examined more closely. 
 
12.0 Management of relapse, treatment failure and drug resistance 
 
12.1 Relapse 
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TB relapse is defined in a patient who has become (and remained) culture-negative 
while receiving therapy but after completion of therapy shows: 
 culture-positive again; 
 or clinical or radiographic deterioration consistent with active TB. 
 
Every effort should be made to establish a diagnosis and obtain microbiological 
confirmation of the relapse to enable testing for drug resistance. IRIS events can mimic 
treatment relapse (see section 10). Strong consideration should be given to obtaining a 
rapid molecular rifampicin resistance test for all HIV-positive patients with relapse or 
treatment failure. These are available in TB reference laboratories and advice should be 
sought from them as soon as the diagnosis is contemplated.  
 
Most relapses occur within 6–12 months of completing therapy. In patients with initially 
drug susceptible TB, who were treated with rifamycin-containing regimens using DOT, 
relapse is with susceptible organisms in nearly all cases. In patients who self-
administered therapy or received a non-rifamycin regimen, relapse incurs a substantial 
risk of acquired drug resistance. 
 
The selection of empirical treatment for patients with relapse should be based on the 
prior treatment regimen and severity of disease: 
I. For patients with prior TB caused by drug susceptible organisms, who received 
DOT with a rifamycin based regimen, initiation of the standard four-drug regimen is 
appropriate until the results of drug susceptibility tests are available. [AII] 
II. For patients with life-threatening TB, at least three additional agents to which the 
organisms are likely to be susceptible should be included, even if the criteria in (I) 
are fulfilled. [AIII] 
III. For patients with relapse, who did not receive DOT, or had treatment interruptions, 
or who were not treated with a rifamycin based regimen, then it should be assumed 
that drug resistance is present. Treatment is initially with isoniazid, rifampicin and 
pyrazinamide plus an additional three agents. Such agents could include a 
fluoroquinolone, an injectable such as amikacin, with or without additional oral 
drugs such as para-aminosalicylic acid (PAS), cycloserine, prothionamide and 
clarithromycin. [AIII] 
 
12.2 Treatment failure 
Treatment failure is defined as continued or recurrently positive cultures during the 
course of anti-tuberculosis therapy. After 3 months of multi-drug therapy for pulmonary 
tuberculosis caused by drug susceptible organisms, up to 98% of patients will have 
negative cultures and show clinical improvement. All patients with positive cultures after 
3 months of appropriate treatment must be evaluated carefully to identify the cause of 
the delayed conversion. Patients whose sputum cultures remain positive after 4 months 
of treatment should be classified treatment failures. 
 
There are many reasons for treatment failure in patients receiving appropriate regimens. 
These include: 
 non-adherence; 
 drug resistance; 
 malabsorption of drugs; 
 laboratory error; 
 extreme biological variation resulting in a prolonged time to respond. 
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 Re-infection with a drug resistant strain  
 
If treatment failure occurs, the case should be referred to a regional centre [1]. M. 
tuberculosis isolates should be sent to a reference laboratory for drug susceptibility 
testing to both first- and second-line agents. One of the fundamental principles in 
managing patients with treatment failure is never to add a single drug to a failing 
regimen, as this leads to acquired resistance to the new drug. Instead, at least two, and 
preferably three, new drugs should be added, to which the patient has not been exposed 
and to which susceptibility is thought likely. Empirical regimens usually include a 
fluoroquinolone, an injectable agent such as amikacin, and an oral agent such as 
cycloserine, prothionamide, clarithromycin or para-aminosalicylic acid (PAS). Once drug 
susceptibility test results are available, the regimen should be adjusted accordingly. 
 
12.3 Management of INH resistance without rifampicin or other significant drug 
resistance  
The ATS and BTS have recommended several treatment regimens for the treatment of 
INH-resistant TB, which include: a) 12 months of rifampicin and ethambutol (12RE); b) 6 
months of rifampicin, ethambutol and pyrazinamide (6REZ); c) 2 months of rifampicin, 
ethambutol and pyrazinamide then 10 months of rifampicin and ethambutol 
(2REZ/10RE); and d) 2 months of rifampicin, ethambutol and pyrazinamide or 
streptomycin then 7 months of rifampicin and ethambutol (2REZ or S/7RE).  
The efficacies of these regimens have not been fully evaluated in prospective trials in 
HIV-positive subjects and we recommend 12 months of rifampicin and ethambutol with 
pyrazinamide also given in the first 2 months (2REZ/10RE).  
If INH resistance is only discovered at 2 months of initial four drug treatment then one 
can either continue with RE for 10 months or continue REZ for a total of six months. In 
patients with extensive disease, one might continue both E and Z with R for 9–12 months 
or even use RE with a quinolone. 
12.4 Multi-Drug resistant-TB (MDR-TB)/and extensively resistant TB XDRTB [195] 
TB resistance to at least isoniazid and rifampicin is known as MDR-TB and isolates are 
at high risk of further acquired drug resistance. Risk factors for MDR-TB include: 
 previous TB treatment; 
 birth, travel or work in an area endemic for MDR-TB; 
 history of poor adherence; 
 sputum smear positive after 2 months; TB therapy or culture positive at 3 
months; 
 homelessness/hostel living. 
 
All such patients should be referred to regional treatment centres, regardless of HIV 
status. There is a web based discussion forum that can be used by the physician 
managing such cases. Further details are available on the BTS website at www.brit-
thoracic.org.uk/tuberculosis.aspx 
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Although patients with strains resistant to rifampicin alone have a better prognosis than 
those with MDR-TB, they are also at increased risk of treatment failure and further 
resistance and should be managed in consultation with an expert. There are no definitive 
randomized or controlled studies to define best regimens for MDR-TB. In principle, 
patients should be given four drugs to which the organism is susceptible. 
Recommendations are therefore based on the resistance profile and expert opinion. The 
optimum duration of treatment of MDR-TB in HIV patients has also not been established, 
but many cases are treated for at least 18 months to 2 years after cultures revert to 
negative.  
The drugs used to treat MDR-TB include the second line and other drugs that are listed 
in Table 3. There are no formal data regarding interactions between these drugs and 
antiretrovirals but a review of the subject has been published [123]. Ethionamide has 
significant interactions because it is metabolized by the CYP450 system, although which 
isoenzyme is unknown. There is no guidance about dose adjustment but therapeutic 
drug monitoring may be useful. There is a potential for renal toxicity with 
aminoglycosides and tenofovir but there are few data on drug interactions between 
antiretrovirals and second-line anti-tuberculous treatment except for clarithromycin. 
Expert advice should be sought through the expert physicians network (www.brit-
thoracic.org.uk/tuberculosis.aspx). 
Novel drugs are being developed for treatment of MDR-TB, e.g. TMC 207, but are not 
available in the UK.  
Surgical resection in the management of pulmonary MDR-TB can be used but results of 
randomized trials are awaited.  
 
   
   
 
12.5 XDR-TB 
Extensively drug-resistant TB (XDR-TB) is defined as TB that is resistant to at least 
isoniazid plus rifampicin, and to fluoroquinolones, and at least one of three injectable 
drugs (capreomycin, kanamycin or amikacin). XDR-TB has a high mortality [196] but is 
fortunately still rare in the UK. As for MDR-TB, all cases should be referred to 
consultants with expertise in management. 
 
12.6 Chemo preventative therapy in MDR/XDR-TB 
In HIV-infected individuals exposed to MDR-TB, chemo-preventative therapy may be 
considered. If given at all it should be based on the drug sensitivity of the index case’s 
isolate. Despite the lack of evidence, the CDC, the American Thoracic Society, and the 
Infectious Diseases Society of America have suggested that for the treatment of latent 
infection in people exposed to MDR-TB a two-drug regimen of pyrazinamide and 
ethambutol or pyrazinamide and a quinolone (levofloxacin, moxifloxacin or ofloxacin) can 
be offered [197]. Further guidance is contained in [4,198].  
 
As with MDR TB in XDR-TB any chemo-preventative therapy should be based on the 
drug sensitivity of the index case.  
 
The balance of benefits versus detriments associated with treatment for latent 
tuberculosis infection in people exposed to MDR-TB or XDR-TB is not clear. The drugs 
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have potential serious adverse effects and any decision to start or not needs careful 
consideration and expert advice. 
  
13.0 Pregnancy and breast-feeding 
Although tuberculosis in pregnancy carries a risk of tuberculosis in the fetus, the main 
problem of tuberculosis in pregnancy is a poor fetal outcome [199]. Treatment should be 
initiated whenever the probability of maternal disease is moderate to high. The initial 
phase should consist of isoniazid, rifampicin and ethambutol. Pyrazinamide is probably 
safe in pregnancy and is recommended by the WHO and the International Union against 
Tuberculosis and Lung Disease (IUATLD). These first-line drugs cross the placenta but 
do not appear to be teratogenic.  
Streptomycin can cause congenital deafness [200] and prothionamide is teratogenic, so 
both should be avoided. Ethionamide causes birth defects at high doses in animals 
[201].  
If pyrazinamide is not included in the initial phase, the minimum duration of therapy is 9 
months. As in the general population pyridoxine 10 mg/day is recommended for all 
women taking isoniazid. In pregnancy antiretroviral pharmacokinetics are variable and 
TDM is recommended. 
Women who are breast-feeding should be given standard TB treatment regimes. [AIII] 
Pregnant women are usually on a PI-boosted HAART regimen and therefore should 
receive rifabutin as part of their antituberculous regimen. There are no adequate and 
well-controlled studies of rifabutin use in pregnant women. No teratogenic effects were 
observed in reproduction studies carried out in rats and rabbits. 
 
14.0 Treatment of latent TB infection – HAART, anti-tuberculosis drugs or both? 
 
14.1 Prophylaxis in those at risk of TB – risks and benefits 
 
Persons from resource-poor countries, especially Sub-Saharan Africa, often present with 
TB as their first manifestation of immunosuppression. Others who are diagnosed with 
HIV have high rates of latent TB infection. Low CD4 cell counts and not being on 
antiretroviral therapy are also associated with an increased risk of reactivation of latent 
tuberculosis [202,203].  
Widespread use of HAART has reduced the risk of developing clinical TB among 
persons infected with HIV. In several studies the risk of TB was up to 80% lower in those 
prescribed HAART. The protective effect was greatest in symptomatic patients and 
those with advanced immune suppression and was not apparent in those with CD4 
counts >350 cells/μL [204–206]. The effect is almost certainly related to improvements in 
systemic immunity (reflected by increasing CD4 cell count) to a point where the risk of 
new infection or reactivation is greatly diminished.  
There have been many short-term controlled trials in HIV-positive persons showing the 
protective effect of chemo-preventative therapy,207–213]. A significant protective effect 
of isoniazid is found only in those who are tuberculin skin test-positive, and appears to 
only last 2 to 4 years as compared with at least 19 years (suggesting protection is 
lifelong) in TB control programs of non-HIV populations where active cases were also 
treated, limiting the risk of any reinfection occurring. This is an important point as the HIV 
populations studied have mainly been in areas of high TB prevalence, where most TB 
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arises from new infection rather than reactivation [53]. Apart from recognized outbreaks, 
there is little evidence to suggest that reinfection (as opposed to reactivation) is a major 
factor in the UK. Chemo-preventative therapy might therefore have a longer duration of 
effect in the UK but there are no data to support this hypothesis. 
There are some data from Brazil to suggest that a combination of HAART and isoniazid 
may be more effective than either alone in controlling TB [205]. The epidemiological 
situation in the UK is different however. 
Chemo-preventative therapy without HAART seemed to have little effect on HIV 
progression and mortality in the long term [211]. There are also theoretical concerns that 
widespread isoniazid monotherapy might speed the emergence of drug resistant TB 
[214]. However, in a recent meta-analysis of 13 studies investigating the risk of 
developing isoniazid resistance as a result of chemopreventative therapy, the relative 
risk for resistance was 1.45 (95% confidence interval 0.85–2.47). Results were similar 
when studies of HIV-uninfected and HIV-infected persons were considered separately. 
Analyses were limited by small numbers and incomplete testing of isolates, and their 
findings did not exclude an increased risk for isoniazid-resistant TB after isoniazid 
preventatative therapy [215].  
 
The other risk of isoniazid preventative therapy is hepatotoxicity. The BTS Joint 
Tuberculosis Committee used a rate of 278/100 000 for serious hepatotoxicity. It may be 
more frequent in HIV-positive patients and those with active viral hepatitis (see section 
7.1) – though the data are conflicting. 
 
14.2 Chemopreventative therapy for latent tuberculosis in HIV-positive patients in 
the UK 
As there are no definitive data from developed countries on whether giving 
chemopreventative therapy to patients with a positive IGRA will reduce the risk of 
developing TB, the available large cohort data from Europe were examined to provide a 
basis for a pragmatic clinical approach to this problem and to calculate the risk of 
developing active tuberculosis [202,203]. The risk of developing active TB versus the 
risk of developing hepatitis on isoniazid prophylaxis was then used as the counterpoint 
to decide on whether chemopreventative therapy should be offered or not. A similar 
exercise has been performed to help decide whether to give chemopreventative therapy 
to patients starting anti-TNF therapy, where the risk of developing TB is balanced 
against the risk of isoniazid-induced hepatitis.  
 
In an HIV-infected individual with a positive IGRA, the risk of developing active TB, and 
therefore the need for chemopreventative therapy, is based on (see Table 9 and flow 
chart): 
 region of origin; 
 current blood CD4 cell count; 
 duration of time on HAART. 
 
HIV-positive patients at increased risk fall into the following groups: 
 Sub Saharan Africa – if length of current antiretroviral therapy is under 2 years, 
whatever the current blood CD4 cell count.  
 medium TB incidence countries – if length of current antiretroviral therapy is 
under 2 years and current CD4 count is less than 500 cells/μL  
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 low incidence countries, e.g. Caucasians from the UK – if not on antiretrovirals, 
or length of current antiretroviral therapy is less than 6 months and current CD4 
count is less than 350 cells/μL. 
 
Patients should be offered screening with IGRA if (and only if) they are in one of these 
groups and would benefit from chemoprophylaxis [BII]. 
 
If the IGRA result is positive then we recommend the patient is given chemoprophylaxis. 
 
If the IGRA result is negative then no chemoprophylaxis is needed. 
 
If a patient is tested with an IGRA outside of these guidelines (not in one of the risk 
groups above), then no chemoprophylaxis is needed, even if the result is positive. 
These recommendations are based on extrapolation from available data and further 
analyses are under way to refine this approach. If an IGRA test is indeterminate then we 
suggest repeating it and if still indeterminate the clinician should use clinical judgment 
regarding whether to give chemopreventative therapy or not. 
  
This Committee is aware that this new guidance will need local interpretation with regard 
to available resource, and that it should be subject to early audit (2010 NICE guidance 
on IGRA testing). Draft NICE guidance suggests using IGRA testing in those patients 
with a CD4 count over 200cells/μL and both an IGRA and tuberculin test in those with 
CD4 counts below this threshold. Although physicians can perform both tests in the 
severely immunosuppressed patients we believe that as there are few data to support 
this strategy doing this would add complexity, cost and difficulties in interpretation and 
believe that an IGRA test alone would be sufficient at every CD4 count count stratum. 
New data would be welcome in guiding physicians in this difficult area. 
 
It is important to note that HIV-positive patients who are in close and prolonged contact 
with patients with proven or assumed active tuberculosis should be screened for TB and 
if no active disease is found chemopreventative therapy recommended.  
 
Though few data are available for patients receiving cancer chemotherapy or prolonged 
high-dose corticosteroids (>20mg od prednisolone for more than 2 months) where the 
prognosis is > 1 year, it may be reasonable to give isoniazid prophylaxis to all those with 
a positive IGRA who do not have active tuberculosis. 
 
14.3 Drug regimens for chemopreventative therapy  
Individuals with a positive Interferon-γ assay but no clinical or radiological evidence of 
active TB are assumed to have latent infection. Active TB should be excluded with a 
detailed history and examination and at least a chest radiograph. Other investigations 
might be necessary, for example lymph node biopsy (if lymphadenopathy), or 
colonoscopy and biopsy (if diarrhoea). It is especially important to consider subclinical 
TB prior to starting HAART because of the risk of IRIS [216] (see also 10.0). 
Alternatives for treating latent tuberculosis: 
 isoniazid for 6 months [210]; [A11] 
 rifampicin with isoniazid for 3 months; [BI] 
 rifampicin for 4 months. [BIII] 
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Shorter courses using other drugs have been tried to help overcome poor adherence. 
Rifampicin and pyrazinamide given daily or twice weekly, for 2 months has been used 
successfully in HIV-positive patients [209,212,213] but is not recommended [DII] 
because in largely non-HIV patients it has been associated with severe or fatal hepatic 
reactions in at least 50 cases in the USA [217].  
 
14.4 Post-treatment prophylaxis 
Studies in areas of high TB prevalence have shown that isoniazid prophylaxis post-
treatment achieves short-term reductions in rates of TB [218,219]. Such a strategy may 
in fact prevent reinfection, which is more common than true reactivation in such settings 
[220]. For maximum benefit the isoniazid would need to be continued long-term, or at 
least until CD4 cell count had substantially risen on HAART, and there are no data to 
support such an approach. It is clear that relapse rates are lower in patients on HAART, 
associated with both improved CD4 cell counts and achieving an undetectable viral load 
[221]. 
Post-treatment TB prophylaxis is therefore not recommended, but HAART should be 
continued. [DII] 
 
   
   
 
15.0 Prevention and control of transmission 
Guidelines for prevention and control of transmission of TB include: 
 National Institute for Health and Clinical Excellence. Tuberculosis: Clinical 
diagnosis and  management of tuberculosis, and measures for its prevention and 
control, 2006; 
 Stopping Tuberculosis in England: An action plan from the Chief Medical Officer, 
published by Department of Health, 7 October 2004; 
 Tuberculosis prevention and treatment: a toolkit for planning, commissioning and 
delivering high-quality services in England, published by Department of Health, 
15 June 2007; 
 The Prevention and Control of Tuberculosis in the United Kingdom published by 
The Interdepartmental Working Group on Tuberculosis, 1998 [4]. 
These are available at: 
www.dh.gov.uk/en/Publichealth/Communicablediseases/Tuberculosis/index.htm 
 
In summary, for good control of TB there should be: 
 recognition that TB is a potential diagnosis; 
 prompt confirmation of diagnosis; 
 no delay in starting treatment; 
 an appropriate drug regimen; 
 supervised therapy; 
 early consideration of drug resistance in non-responding patients. 
 
Hospital care of patients with potential or known TB requires: 
 appropriate isolation of patients; 
 risk assessment for drug resistance; 
 adequate negative pressure rooms which are properly monitored [4]; 
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 aerosol generating procedures (bronchoscopy, sputum induction or nebuliser 
treatment) should only take place in negative pressure rooms; 
 consider all patients potentially infectious until proven otherwise; 
 no mixing of HIV-infected or other immunosuppressed patients with TB patients; 
 hospital TB control plan based on risk assessment; 
 adequate protection of health care workers and other contacts. 
 
15.1 Notification 
TB is a notifiable disease in the UK as it is in many other countries. 
If the patient is concerned about disclosure of HIV status following notification by an HIV 
physician, then the notification can be done by any physician involved in clinical care.  
Contact tracing should follow the NICE guidelines [1] but requires considerable 
sensitivity. 
 
 
 
16.0 Death and clinico-pathological audit 
Despite diagnosis and treatment, patients with HIV and tuberculosis still die. It is 
important that as many such patients as feasible are examined by autopsy. This 
categorises the pathology and enables audit of medical practice. The significant 
categories of causes of death include: 
 active, progressive tuberculosis; 
 secondary effects of tuberculosis (e.g. lung haemorrhage, meningovascular 
obstruction); 
 IRIS affecting one or more critical organs (e.g. lung, brain); 
 anti-tuberculosis drug toxicity; 
 other HIV- or non-HIV-related disease in a person effectively treated for TB; 
 other disease in a person diagnosed with and treated for TB, without laboratory 
confirmation, who shows at autopsy no evidence of having had TB. 
 
Culture of tuberculous autopsy tissue should be performed routinely, to evaluate drug 
sensitivity and bacterial viability. 
 
Autopsies are either requested by clinicians or commanded by a Coroner (in UK) or 
Procurator Fiscal (in Scotland). If the autopsy is coronial, every endeavour should be 
made to obtain the autopsy report for clinical audit. Before any autopsy, discussion 
about the clinico-pathological issues with the pathologist is recommended.  
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17.0 Tables 
Table 1: Abbreviations  
AIDS   acquired immune deficiency syndrome 
ALT   alanine aminotransferase  
AST   aspartate aminotransferase 
ATS  American Thoracic Society  
AUC   area under the curve 
BHIVA  British HIV Association 
BTS  British Thoracic Society 
CDC   Centers for Disease Control and Prevention, USA 
CNS   central nervous system 
CYP   cytochrome 450 
d4T   stavudine 
ddC   zalcitabine  
ddI   didanosine 
DOT   directly observed therapy  
E   ethambutol 
H   isoniazid 
HAART  highly active antiretroviral therapy 
HIV   human immunodeficiency virus 
INH  isoniazid 
IGRA  interferon gamma release assay 
IRD  immune reconstitution disease  
IRIS   immune reconstitution inflammatory syndrome  
MDR-TB  multi drug resistant tuberculosis 
NICE  National Institute for Health and Clinincal Excellence 
NRTI  nucleoside/nucleotide reverse transcriptase inhibitor 
NNRTI  non-nucleoside reverse transcriptase inhibitor 
PAS   para-aminosalicylic acid  
PCR   polymerase chain reaction 
PgP  P-glycoprotein 
PI   protease inhibitor 
R   rifampicin 
TB   tuberculosis 
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TDM   therapeutic drug monitoring  
TST  tuberculin skin test 
WHO   World Health Organization 
XDR-TB extensively drug-resistant TB 
Z   pyrazinamide 
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Table 2: Strength of treatment recommendations based on 
quality of evidence*  
 
Strength of the recommendation: 
A Preferred; should generally be offered 
B Alternative; acceptable to offer 
C Offer when preferred or alternative regimens cannot be given 
D Should generally not be offered 
E Should never be offered 
 
Quality of evidence supporting the recommendation: 
I. At least one properly randomized trial with clinical end points 
II. Clinical trials either not randomized or conducted in other populations 
III. Expert opinion 
 
* Adapted from Gross PA, Barrett TL, Dellinger EP et al. Clin Infect Dis 1994; 18: 421. 
 
 
 
Table 3: Drugs used in the treatment of TB 
 
First-line drugs    Second-line drugs 
______________________________________________________________________ 
isoniazid     sparfloxacin, ofloxacin, levofloxacin, moxifloxacin  
rifampicin*     rifabutin* 
pyrazinamide    streptomycin, amikacin, kanamycin 
ethambutol    cycloserine 
     protionamide, ethionamide  
capreomycin,  
 
`     para-aminosalicylic acid 
Other drugs used in the treatment of MDR-TB but with few or no clinical outcome data 
clarithromycin, azithromycin 
 amoxicillin with clavulanic acid 
linezolid** 
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* Rifabutin may be substituted for rifampicin as a first-line drug in some situations, e.g. 
drug interactions. It is used in second line when there is rifampicin resistance but 
rifabutin sensitivity remains.  
Only physicians skilled in the treatment of TB should prescribe TB regimens. 
** The maximum recommended duration of linezolid is usually 28 days. All patients on 
linezolid should have their complete blood counts monitored weekly and be advised to 
report any new signs and symptoms. There have been reports of optic and peripheral 
neuropathy, especially after 28 days of therapy. 
 See BNF for standard doses of individual drugs and fixed dose formulations. 
Tables 4–7: Drug interactions 
More information at University of Liverpool website: www.hiv-druginteractions.org 
Dose adjustments are described below for antiretrovirals given with rifampicin, rifabutin and 
clarithromycin.  
No dosage adjustments are advised with isoniazid, pyrazinamide, streptomycin, amikacin, 
kanamycin, ethionamide, azithromycin, ofloxacin or ciprofloxacin.  
 
Key for interaction tables 
No Interaction – use standard doses 
Potential Interaction – see advice 
Definite interaction – do not combine 
 
Table 4: Nucleoside reverse transcriptase inhibitors (NRTIs)  
 
 
Rifampicin Rifabutin 
Abacavir  
Didanosine EC  
Emtricitabine  
Lamivudine  
Stavudine  
Tenofovir  
Zidovudine  
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Table 5: Non-nucleoside reverse transcription inhibitors (NNRTIs)  
 Rifampicin Rifabutin 
Efavirenz 
Efavirenz levels  by 20–
30% 
Efavirenz increased to 
800mg daily if weight 
>60kg 
Efavirenz at 600mg daily 
if weight <60kg 
Rifampicin at standard 
dose 

Rifabutin levels  by 
38%.  
Rifabutin increased to 
450mg daily 
Efavirenz at standard 
dose 
Nevirapine 
Nevirapine levels  20–
55% 
No change in rifampicin 
Not recommended 

Use standard doses but 
little data so not 
recommended  
Etravirine No data available 
Use standard doses but 
little data so use with 
caution 
TMC-278   
TMC-278 levels  90% 
Do not use 

TMC-278 levels  50% 
Double dose TMC-278 
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Table 6: Protease inhibitors (PIs)  
PI Rifampicin Rifabutin 
Atazanavir  80%  level atazanavir 
Do not use 
 Reduce rifabutin to 
150mg daily 
Atazanavir/ 
Ritonavir 
  level atazanavir 
Do not use 
 Reduce rifabutin to 
150mg 3x per week 
Darunavir/ 
Ritonavir 
 No data 
Do not use 
 Reduce rifabutin to 
150mg 3x per week 
Fosamprenavir/ 
Ritonavir 
  levels amprenavir 
Do not use 
 Reduce rifabutin to 
150mg 3x per week 
Lopinavir/ 
Ritonavir 
 75%  level lopinavir 
Higher doses cause 
heptatotoxicity 
Do not use 
 Reduce rifabutin to 
150mg 3x per week 
Ritonavir as single agent  35%  level ritonavir 
Can be used at 600mg twice 
daily but very poorly 
tolerated 
 
Saquinavir/ 
Ritonavir 
  level saquinavir 
Higher doses cause 
heptatotoxicity 
Do not use 
 Reduce rifabutin to 
150mg 3x per week 
Tipranavir/ 
Ritonavir 
 80%  level tipranavir 
Do not use 
 Reduce rifabutin to 
150mg 3x per week 
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Table 7: Integrase inhibitors and entry inhibitors  
 Rifampicin Rifabutin 
Elvitegravir 
Elvitegravir levels   
Do not use 
No data  
Raltegravir 
Raltegravir levels  60% 
Even at 800mg bd use 
with caution as Cmin  % 
Use standard doses 
Maraviroc Use with caution  
Maraviroc levels   
Double maraviroc dose 
to 600mg bd  

Use standard doses 
Enfuvirtide (T-20) 
No interaction 
Use standard doses 

No interaction 
Use standard doses  
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Table 8 
Guidelines for the re-introduction of anti-tuberculosis chemotherapy following 
elevation of liver function tests or cutaneous reaction grade 1–3  
Day  Isoniazid  Rifampicin     Pyrazinamide  
______________________________________________________________________ 
       
1  50mg  
2  150mg  
3  300mg  
4  300mg  75mg  
5  300mg  150mg  
6  300mg  300mg  
7  300mg  450mg <50kg or 600mg >50kg  
8 300mg  450mg/600mg    250mg  
9 300mg  450mg/600mg    500mg  
10 300mg   450mg/600mg    1g  
11 300mg  450mg/600mg    1.5g <50kg or 2g >50kg  
12  300mg  450mg/600mg    1.5g/2g  
13  300mg  450mg/600mg    1.5g/2g 
______________________________________________________________________ 
If the reaction is severe, start with one-tenth of the first-day dose for each drug.  
Adapted from a reintroduction protocol for cutaneous reactions (Girling DJ. Adverse 
effects of antituberculous drugs. Drugs 1982; 23: 56–74). 
Patients who are infectious should be treated with two active drugs whilst standard 
therapy is reintroduced. Suitable agents would be ethambutol and streptomycin or 
ethambutol and ofloxacin/moxifloxacin (note reports of severe hepatotxicity with 
moxifloxacin). In patients who are non-infectious, ethambutol should be started once the 
other three drugs are at full dose.  
An alternative reintroduction regimen was described in 1996 for patients with hepatotoxic 
adverse reactions [222] and adopted by the Joint Tuberculosis Committee in 1998 [55]: 
 
Once liver function is normal the original drugs can be reintroduced sequentially in the 
order isoniazid, rifampicin, pyrazinamide, with daily monitoring of the patient’s condition 
and liver function. Isoniazid should be introduced initially at 50mg/day increasing 
sequentially to 300mg/day after 2–3 days if no reaction occurs and then continued. After 
a further 2–3 days without reaction rifampicin at a dose of 75mg/day can be added, 
increasing to 300mg/day after 2–3 days, and then after a further 2–3 days without 
reaction to 450mg(<50mg) or 600mg(>50kg) per day as appropriate for the patient’s 
weight, and then continued. Finally pyrazinamide can be added at 250mg/day, 
increasing to 1gm/day after 2–3 days and then 1.5gm (<50kg) or 2.0gm (>50kg) per day. 
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Example of alternative schedule 
 
 
Day  Isoniazid  Rifampicin    Pyrazinamide  
______________________________________________________________________ 
       
1  50mg  
2  50mg  
3  150mg  
4  300mg   
5  300mg   
6  300mg  75mg  
7  300mg  75mg 
8 300mg  150mg     
9 300mg  300mg     
10 300mg   300mg     
11 300mg  450mg <50kg or 600mg >50kg 
12  300mg  450mg/600mg     
13  300mg  450mg/600mg    
14 300mg  450mg/600mg   250mg 
15  300mg  450mg/600mg   250mg  
16  300mg  450mg/600mg   500mg 
17 300mg  450mg/600mg   1g 
18  300mg  450mg/600mg   1.5g <50kg or 2.0g >50kg 
19  300mg  450mg/600mg   1.5g/2g 
 
 
Table 9 
 
Recommendations for Chemopreventative Therapy in HIV-Infected Persons by 
IGRA Status and Epidemiologic Risk Factors [202,203] 
 
IGRA positive 
 
Sub Saharan Africans → whatever blood CD4 cell count 
and length HAART <2years 
 
Medium incidence  → blood CD4 count < 500 cells/μL  
and length HAART <2years 
 
 
Low incidence    →    blood CD4 count <350 cells/μL  
and not on treatment or on treatment < 6/12 
 
IGRA negative 
 
No chemopreventative therapy 
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Footnote  
Regions of origin (1) sub-Sahara Africa; 
 (2) medium-risk regions, including Eastern Europe, Central Asia, North Africa and the 
Middle East, South Asia, East Asia, and the Caribbean; and 
 (3) low-risk regions. 
 
 
 
Table 10  
 
Case definition of IRIS [184] 
 
Although this was developed for a resource-poor setting it is comprehensive and is a 
useful checklist. 
 
There are three components to this case definition: 
(A) Antecedent requirements 
Both of the two following requirements must be met: 
• Diagnosis of tuberculosis: the tuberculosis diagnosis was made before starting ART 
and this should fulfil WHO criteria for diagnosis of smear-positive pulmonary 
tuberculosis, smear-negative pulmonary tuberculosis or extrapulmonary tuberculosis 
[55]. 
 
• Initial response to tuberculosis treatment: the patient’s condition should have stabilised 
or improved on appropriate tuberculosis treatment before ART initiation – e.g., cessation 
of night sweats, fevers, cough, weight loss. (Note: this does not apply to patients starting 
ART within 2 weeks of starting tuberculosis treatment since insufficient time may have 
elapsed for a clinical response to be reported.) 
 
(B) Clinical criteria 
The onset of tuberculosis-associated IRIS manifestations should be within 3 months of 
ART initiation, reinitiation, or regimen change because of treatment failure. 
 
Of the following, at least one major criterion or two minor clinical criteria are required: 
 
Major criteria 
 
• New or enlarging lymph nodes, cold abscesses, or other focal tissue involvement – 
e.g., tuberculous arthritis 
 
• New or worsening radiological features of tuberculosis (found by chest radiography, 
abdominal ultrasonography, CT, or MRI) 
 
• New or worsening CNS tuberculosis (meningitis or focal neurological deficit – e.g.  
caused by tuberculoma) 
 
• New or worsening serositis (pleural effusion, ascites, or pericardial effusion) 
 
Minor criteria 
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• New or worsening constitutional symptoms such as fever, night sweats, or weight loss 
 
• New or worsening respiratory symptoms such as cough, dyspnoea, or stridor 
 
• New or worsening abdominal pain accompanied by peritonitis, hepatomegaly, 
splenomegaly, or abdominal adenopathy 
 
(C) Alternative explanations for clinical deterioration must be excluded if possible* 
• Failure of tuberculosis treatment because of tuberculosis drug resistance 
• Poor adherence to tuberculosis treatment 
• Another opportunistic infection or neoplasm (it is particularly important to exclude an 
alternative diagnosis in patients with smear-negative pulmonary tuberculosis and 
extrapulmonary tuberculosis where the initial tuberculosis diagnosis has not been 
microbiologically confirmed). 
 
18.0 Key Points: 
 
18.1 Treatment of uncomplicated non-CNS tuberculosis 
A four-drug regimen of rifampicin, isoniazid, pyrazinamide and ethambutol for 2 months; 
followed by rifampicin and isoniazid for 4 months. 
 
18.2 Treatment of CNS or MDR-TB 
A prolonged treatment duration is recommended. 
TB meningitis is treated for at least 9 months. 
In MDR-TB treatment for up to 2 years may be indicated. 
 
18.3 Treatment schedule 
Daily therapy is recommended. 
If therapy is given 3 or 5 times per week it should be supervised, preferably as DOT. 
 
18.4 Liver disease 
Patients with pre-existing liver disease need their liver function tests monitored closely. 
They need to be advised to present immediately if they develop vomiting, abdominal 
pain or jaundice. 
 
18.5 Molecular diagnostic techniques 
Molecular diagnostic tests can give rapid identification of mycobacterial species.  
PCR probes can rapidly detect resistance to rifampicin. 
These results can help decisions about treatment and infection control measures. 
 
18.6 Notification of TB 
All patients with TB, regardless of HIV status, must be notified. 
 
18.7 Infection Control 
All potentially infectious patients should be managed in appropriate isolation facilities, 
such as negative pressure rooms, with staff and visitors wearing high-efficiency 
particulate filtration masks. 
 
18.8 Drug interactions 
Complex drug interactions occur between rifamycins and antiretroviral drugs and other 
drugs that may affect dosages and dosing frequencies. 
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18.8 Starting HAART 
Starting HAART in patients on antituberculous medication should take into consideration 
primarily the CD4 cell count but other factors such as adherence, potential toxicities and 
drug–drug interactions are also important. 
 
18.9 Chemopreventative therapy 
IGRA tests are preferred to Tuberculin skin tests (eg Mantoux). Chemo-preventative 
therapy should be considered for all IGRA positive HIV-infected patients dependent on a 
risk assessment based on country of origin, blood CD4 count and length of time on 
HAART. 
 
Appendix 
 
BHIVA Guidelines Writing Group on TB Coinfection: 
 
Group chair and lead: Dr Anton Pozniak, Chelsea & Westminster Hospital, London. 
 
Members: Dr Katherine Coyne, Homerton University Hospital, London; Prof Rob Miller, 
Royal Free and University College Medical School, London; Dr Marc Lipman, Royal Free 
Hospital, London; Dr Andrew Freedman, Cardiff University School of Medicine; Prof 
Peter Ormerod, Royal Blackburn Hospital; Prof Margaret Johnson, Royal Free and 
University College Medical School, London; Dr Simon Collins, HIV i-base, London; Prof 
Sebastian Lucas, Guy’s, King’s and St Thomas’ School of Medicine, London. 
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